Aurora to Participate in the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Aurora (NASDAQ: ACB) will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CFO Simona King will join a fireside chat and investor meetings to discuss international leadership and manufacturing trends in medical cannabis.
Webcast registration is available on the company's Investor Info page and a replay will be accessible for approximately 90 days. The company also announced completion of the previously disclosed Bevo transaction dated February 4, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – ACB
In the Feb 18 session, ACB declined 1.39%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | IR / branding | Positive | -2.3% | Nasdaq closing bell ceremony to spotlight global medical cannabis strategy. |
| Feb 11 | Intl expansion | Positive | -3.4% | Launch of new THC flower and resin products in Australia and New Zealand. |
| Feb 04 | ATM offering | Negative | -7.6% | Prospectus supplement for at-the-market program up to US$100M common shares. |
| Feb 04 | Earnings update | Positive | -7.6% | Q3 FY2026 results with higher revenue, positive EBITDA and reaffirmed guidance. |
| Feb 03 | Digital expansion | Positive | +3.6% | Launch of localized European medical websites and central hub auroramedicine.com. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ACB news often met with weak or negative price reactions, even when operational updates were positive (international expansion, earnings, web launches). Dilutive or capital-raising news, such as the ATM program, aligned with sharper selloffs.
Over the past weeks, Aurora has focused on global medical growth and capital flexibility. On Feb 3, it launched new European websites, which saw a 3.57% gain. However, Q3 FY2026 results on Feb 4 and an accompanying US$100M ATM program both coincided with a 7.64% drop, despite revenue and EBITDA metrics. Subsequent Australia/New Zealand portfolio expansion and a Nasdaq bell-ringing announcement on Feb 11–12 also saw negative reactions, underscoring investor sensitivity to dilution and execution risk ahead of today’s conference and Bevo transaction update.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASDAQ | TSX: ACB
Conference Details
DATE: Monday, March 2, 2026
TIME: 11:10am Eastern Time | 9:10am Mountain Time
WEBCAST: Click Here
The fireside chat will be hosted by Derek Lessard, VP of Equity Research at TD Cowen. The discussion will explore Aurora's international leadership, shifts reshaping the global medical cannabis landscape, advancements in Canadian manufacturing excellence, and the broader market forces influencing the industry's growth.
To listen to the live audio webcast, please register using the weblink above, which has also been posted to the Company's "Investor Info" section at https://www.auroramj.com/investors/ under "Events". A replay of the presentation will be available using the same link for approximately 90 days.
Further, the Company announces that it has completed the transaction with Bevo Agtech Inc. ("Bevo"), previously announced on February 4, 2026 (the "Bevo Transaction"). Full details of the Bevo Transaction can be found in the February 4, 2026 press release located under the Company's profile at www.sedarplus.ca.
About Aurora
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across
Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming participation at the TD Cowen 46th Annual Health Care Conference, as well as those related to the Company's global medical cannabis market leadership.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-to-participate-in-the-td-cowen-46th-annual-health-care-conference-302691035.html
SOURCE Aurora Cannabis Inc.